14207-66-0

Basic information

• Product Name: 1,2-Benzenediamine, N-(3-fluorophenyl)-
• CAS NO: 14207-66-0
• Molecular Formula: C12H11FN2
• Molecular Weight: 202.231
• Mol File: 14207-66-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1,2-Benzenediamine, N-(3-fluorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Benzenediamine, N-(3-fluorophenyl)-(14207-66-0)
• EPA Substance Registry System: 1,2-Benzenediamine, N-(3-fluorophenyl)-(14207-66-0)

Safety Data

• Hazardous Substances Data: 14207-66-0(Hazardous Substances Data)

Upstream product

• 1073-06-9 3-fluorobromobenzene 
• 88-74-4 2-nitro-aniline 
• 322-77-0 N-(3-fluorophenyl)-2-nitroaniline 

Downstream Products

• 1353732-25-8 5-(3-fluorophenyl)-3-(4-tetrahydropyranyl)imino-2-(2-methoxy-3-pyridyl)amino-3,5-dihydrophenazine 
• 1353732-23-6 5-(3-fluorophenyl)-3-isopropylimino-2-(2-methoxy-3-pyridyl)amino-3,5-dihydrophenazine 

Relevant articles and documents

Synthesis and biological evaluation of novel 2-methoxypyridylamino- substituted riminophenazine derivatives as antituberculosis agents

Clofazimine, a member of the riminophenazine class, is one of the few antibiotics that are still active against multidrug-resistant Mycobacterium tuberculosis (M. tuberculosis). However, the clinical utility of this agent is limited by its undesirable physicochemical properties and skin pigmentation potential. With the goal of maintaining potent antituberculosis activity while improving physicochemical properties and lowering skin pigmentation potential, a series of novel riminophenazine derivatives containing a 2-methoxypyridylamino substituent at the C-2 position of the phenazine nucleus were designed and synthesized. These compounds were evaluated for antituberculosis activity against M. tuberculosis H37Rv and screened for cytotoxicity. Riminophenazines bearing a 3-halogen- or 3,4-dihalogen-substituted phenyl group at the N-5 position exhibited potent antituberculosis activity, with MICs ranging from 0.250.01 μg/mL. The 3,4-dihalogensubstituted compounds displayed low cytotoxicity, with IC50 values greater than 64 μg/mL. Among these riminophenazines, compound 15 exhibited equivalent in vivo efficacy against M. tuberculosis infection and reduced skin discoloration potential in an experimental mouse infection model as compared to clofazimine. Compound 15, as compared to clofazimine, also demonstrated improved physicochemical properties and pharmacokinetic profiles with a short half-life and less drug tissue accumulation. This compound is being evaluated as a potential drug candidate for the treatment of multidrug resistant tuberculosis.

Design, synthesis and antifungal evaluation of novel pyrazole carboxamides with diarylamines scaffold as potent succinate dehydrogenase inhibitors

Sixteen novel pyrazole carboxamides with diarylamines scaffold were designed, synthesized and characterized in detail via 1H NMR, 13C NMR and ESI-HRMS. Preliminary bioassays showed that some of the target compounds exhibited good ant

ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE

The present invention is directed to aryl sulfamide derivatives of formula (I): or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic neuropathy, pain, and other diseases or disorders.